Compare Nvidia Corp (NVDA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs ResMed Inc. — how do they compare? Nvidia Corp trades at $206.39 (market cap $4.92T), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: Nvidia Corp is far larger — about 170.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| NVDA | RMD | |
|---|---|---|
Market Cap | $4.92T | $28.81B |
Sector | Technology | Health |
52-Week High | $235.75 | $293.73 |
52-Week Low | $165.17 | $182.82 |
Enterprise Value | $4.86T | $27.99B |
Dividend Yield | 0.49% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamentals. Recent earnings beats and robust profitability margins highlight operational strength. The stock is supported by a consensus analyst price target of $325.86, though it faces technical resistance near $210.
Outlook remains positive driven by AI chip demand, but risks include competition and market volatility. Revenue growth acceleration and high institutional ownership suggest long-term potential, yet valuation multiples require sustained execution to justify further upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
